Subtopic Deep Dive
Therapeutic Options in Relapsing Polychondritis
Research Guide
What is Therapeutic Options in Relapsing Polychondritis?
Therapeutic options in relapsing polychondritis encompass corticosteroids, immunosuppressants, and biologics including anti-TNF agents and IL-6 inhibitors evaluated in observational studies for reducing relapse rates and improving organ-specific outcomes.
Observational cohorts assess glucocorticoids as first-line therapy with immunosuppressants like methotrexate for steroid-sparing effects (Kingdon et al., 2017; 129 citations). Biologics such as infliximab, rituximab, and tocilizumab show efficacy in refractory cases (Kemta Lekpa et al., 2011; 99 citations; Loricera et al., 2014; 93 citations). Over 20 papers since 2011 review these approaches, highlighting airway complication management.
Why It Matters
Therapies target high mortality from tracheobronchial involvement, with UK cohort data showing over twofold excess mortality versus general population (Hazra et al., 2015; 163 citations). Biologics like tocilizumab achieve remission in refractory aortitis associated with polychondritis (Loricera et al., 2014; 93 citations). These options guide rheumatologists in managing rare cases with diagnostic delays (Kingdon et al., 2017; 129 citations; Mathian et al., 2016; 121 citations).
Key Research Challenges
Lack of Randomized Trials
No RCTs exist due to rarity, relying on case series and observational data (Mathian et al., 2016; 121 citations). This limits evidence grading for biologics efficacy (Kemta Lekpa et al., 2011; 99 citations).
Refractory Airway Disease
Tracheobronchial collapse resists standard immunosuppression, driving mortality (Hazra et al., 2015; 163 citations). Biologics show variable organ-specific responses (Kingdon et al., 2017; 129 citations).
VEXAS Overlap Complications
Somatic UBA1 mutations in VEXAS syndrome complicate polychondritis therapy with hematologic manifestations (Obiorah et al., 2021; 221 citations). Standard immunosuppressants risk macrophage activation (Staels et al., 2021; 97 citations).
Essential Papers
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in <i>UBA1</i>
Ifeyinwa E. Obiorah, Bhavisha A. Patel, Emma M. Groarke et al. · 2021 · Blood Advances · 221 citations
Abstract Somatic mutations in UBA1 involving hematopoietic stem and myeloid cells have been reported in patients with the newly defined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somat...
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS
Caspar I. van der Made, Judith Potjewijd, Annemiek Hoogstins et al. · 2021 · Journal of Allergy and Clinical Immunology · 203 citations
Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study
Nisha C. Hazra, Alex Dregan, Judith Charlton et al. · 2015 · Lara D. Veeken · 163 citations
The incidence of relapsing polychondritis may be lower than previously estimated, and diagnostic misclassification and delay are common. Mortality in relapsing polychondritis is more than twice tha...
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
Marcela A. Ferrada, Sinisa Savic, Daniela Ospina Cardona et al. · 2022 · Blood · 163 citations
Abstract Somatic mutations in UBA1 cause vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory somatic (VEXAS) syndrome, an adult-onset inflammatory disease with an overlap of hemato...
Relapsing polychondritis: a clinical review for rheumatologists
Jack Kingdon, Joseph Roscamp, Shirish Sangle et al. · 2017 · Lara D. Veeken · 129 citations
Relapsing polychondritis (RPC) is a rare autoimmune rheumatic disorder that is traditionally classified as a systemic vasculitis. It is characterized by inflammation of cartilage, and typical prese...
Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use
Alexis Mathian, Makoto Miyara, Fleur Cohen‐Aubart et al. · 2016 · Best Practice & Research Clinical Rheumatology · 121 citations
Immunopathologic Studies in Relapsing Polychondritis
Jerome H. Herman, Marie V. Dennis · 1973 · Journal of Clinical Investigation · 116 citations
Serial studies have been performed on three patients with relapsing polychondritis in an attempt to define a potential immunopathologic role for degradation constituents of cartilage in the causati...
Reading Guide
Foundational Papers
Start with Herman and Dennis (1973; 116 citations) for immunopathology basis; Kemta Lekpa et al. (2011; 99 citations) for biologics introduction; Sharma et al. (2013; 109 citations) for clinical overview.
Recent Advances
Kingdon et al. (2017; 129 citations) for rheumatologist review; Mathian et al. (2016; 121 citations) for 2016 treatment update; Obiorah et al. (2021; 221 citations) for VEXAS integration.
Core Methods
Observational cohorts measure relapse rates; GRADE evidence from case series; biologics assessed via organ-specific remission (e.g., tocilizumab in aortitis, Loricera et al., 2014).
How PapersFlow Helps You Research Therapeutic Options in Relapsing Polychondritis
Discover & Search
Research Agent uses searchPapers and citationGraph on 'relapsing polychondritis biologics' to map 20+ papers from Kemta Lekpa et al. (2011; 99 citations), revealing clusters around tocilizumab and anti-TNF. exaSearch uncovers VEXAS overlaps like Obiorah et al. (2021; 221 citations); findSimilarPapers extends to Loricera et al. (2014; 93 citations).
Analyze & Verify
Analysis Agent applies readPaperContent to extract relapse rates from Kingdon et al. (2017), then verifyResponse with CoVe chain-of-verification flags inconsistencies across Mathian et al. (2016). runPythonAnalysis performs meta-analysis on GRADE-graded evidence from 10 biologics papers, computing pooled remission rates with pandas statistical verification.
Synthesize & Write
Synthesis Agent detects gaps in VEXAS-specific therapies via contradiction flagging between Obiorah et al. (2021) and traditional reviews. Writing Agent uses latexEditText for therapy comparison tables, latexSyncCitations for 15 references, and latexCompile for publication-ready review; exportMermaid generates treatment algorithm diagrams.
Use Cases
"Extract and plot biologic remission rates from relapsing polychondritis papers"
Research Agent → searchPapers('biologics relapsing polychondritis') → Analysis Agent → readPaperContent (Kemta Lekpa 2011) → runPythonAnalysis (pandas meta-analysis plot) → matplotlib remission rate bar chart output.
"Draft LaTeX review of tocilizumab in refractory polychondritis aortitis"
Research Agent → citationGraph('tocilizumab polychondritis') → Synthesis Agent → gap detection → Writing Agent → latexEditText (intro+results) → latexSyncCitations (Loricera 2014) → latexCompile → PDF review export.
"Find code for analyzing UBA1 mutation therapy responses in VEXAS"
Research Agent → paperExtractUrls (Obiorah 2021) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → runPythonAnalysis (reproduced mutation frequency stats) → verified code notebook.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ polychondritis papers) → citationGraph → GRADE grading → structured report on therapy efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify biologic relapse reductions across Hazra (2015) and Kingdon (2017). Theorizer generates hypotheses on VEXAS-targeted inhibitors from Obiorah (2021) literature synthesis.
Frequently Asked Questions
What defines therapeutic options in relapsing polychondritis?
Corticosteroids as first-line, followed by methotrexate and biologics like anti-TNF, rituximab, tocilizumab for refractory cases (Kingdon et al., 2017; Mathian et al., 2016).
What methods evaluate these therapies?
Observational cohorts track relapse rates and organ responses; biologics reviewed in case series without RCTs (Kemta Lekpa et al., 2011; 99 citations).
What are key papers on biologics?
Kemta Lekpa et al. (2011; 99 citations) reviews anti-TNF and rituximab; Loricera et al. (2014; 93 citations) shows tocilizumab efficacy in aortitis.
What open problems remain?
No RCTs due to rarity; VEXAS overlap needs mutation-specific therapies; airway mortality persists despite biologics (Hazra et al., 2015; Obiorah et al., 2021).
Research Otitis Media and Relapsing Polychondritis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Therapeutic Options in Relapsing Polychondritis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers